Profiling protein expression in circulating tumour cells using microfluidic western blotting

Circulating tumour cells (CTCs) are rare tumour cells found in the circulatory system of certain cancer patients. The clinical and functional significance of CTCs is still under investigation. Protein profiling of CTCs would complement the recent advances in enumeration, transcriptomic and genomic characterization of these rare cells and help define their characteristics. Here we describe a microfluidic western blot for an eight-plex protein panel for individual CTCs derived from estrogen receptor-positive (ER+) breast cancer patients. The precision handling and analysis reveals a capacity to assay sparingly available patient-derived CTCs, a biophysical CTC phenotype more lysis-resistant than breast cancer cell lines, a capacity to report protein expression on a per CTC basis and two statistically distinct GAPDH subpopulations within the patient-derived CTCs. Targeted single-CTC proteomics with the capacity for archivable, multiplexed protein analysis offers a unique, complementary taxonomy for understanding CTC biology and ascertaining clinical impact.

[1]  Eugene J. Lim,et al.  Microfluidic, marker-free isolation of circulating tumor cells from blood samples , 2014, Nature Protocols.

[2]  O. Ornatsky,et al.  Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry. , 2009, Analytical chemistry.

[3]  S. Gygi,et al.  Correlation between Protein and mRNA Abundance in Yeast , 1999, Molecular and Cellular Biology.

[4]  M. Hung,et al.  The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines , 2010, Breast cancer : basic and clinical research.

[5]  Chichung Wang,et al.  Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. , 2014, Methods.

[6]  A. De Benedetti,et al.  Overexpression of the proto‐oncogene/translation factor 4E in breast‐carcinoma cell lines , 1996, International journal of cancer.

[7]  Gordon B Mills,et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.

[8]  Rajan P Kulkarni,et al.  Size-selective collection of circulating tumor cells using Vortex technology. , 2014, Lab on a chip.

[9]  S. Digumarthy,et al.  Isolation of rare circulating tumour cells in cancer patients by microchip technology , 2007, Nature.

[10]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[11]  M. Gallas,et al.  Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5 , 2012, Oncogene.

[12]  L. Hood,et al.  Integrated barcode chips for rapid, multiplexed analysis of proteins in microliter quantities of blood , 2008, Nature Biotechnology.

[13]  Stephen L. Abrams,et al.  Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. , 2007, Biochimica et biophysica acta.

[14]  Valerie Speirs,et al.  Breast cancer cell lines: friend or foe? , 2003, Breast Cancer Research.

[15]  Corbin E. Meacham,et al.  Tumour heterogeneity and cancer cell plasticity , 2013, Nature.

[16]  A. Luini,et al.  Changes in Circulating Tumor Cell Detection in Patients with Localized Breast Cancer Before and After Surgery , 2010, Annals of Surgical Oncology.

[17]  E. Winzeler,et al.  Protein pathway and complex clustering of correlated mRNA and protein expression analyses in Saccharomyces cerevisiae , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  P. Chattopadhyay,et al.  Seventeen-colour flow cytometry: unravelling the immune system , 2004, Nature Reviews Immunology.

[19]  M. Cristofanilli.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2006, Seminars in oncology.

[20]  Aaron M. Streets,et al.  Microfluidic single-cell whole-transcriptome sequencing , 2014, Proceedings of the National Academy of Sciences.

[21]  Raj Kumar,et al.  The Dynamic Structure of the Estrogen Receptor , 2011, Journal of amino acids.

[22]  Amy E. Herr,et al.  Single-Cell Western Blotting after Whole-Cell Imaging to Assess Cancer Chemotherapeutic Response , 2014, Analytical chemistry.

[23]  T. Fehm,et al.  Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status , 2007, Breast Cancer Research.

[24]  Ling Xu,et al.  Single-cell codetection of metabolic activity, intracellular functional proteins, and genetic mutations from rare circulating tumor cells. , 2015, Analytical chemistry.

[25]  Jeffrey R. Whiteaker,et al.  Proteogenomic characterization of human colon and rectal cancer , 2014, Nature.

[26]  P. Bahadur,et al.  Mixed Micelles of Triton X‐100 and Sodium Dodecyl Sulfate and Their Interaction with Polymers , 2003 .

[27]  Valerie Speirs,et al.  Choosing the right cell line for breast cancer research , 2011, Breast Cancer Research.

[28]  J. C. Love,et al.  Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits. , 2014, Integrative biology : quantitative biosciences from nano to macro.

[29]  R. Herbst,et al.  Use of novel second-line targeted therapies in non-small cell lung cancer. , 2006, Seminars in oncology.

[30]  Clifford B Saper,et al.  An open letter to our readers on the use of antibodies , 2005, The Journal of comparative neurology.

[31]  Sridhar Ramaswamy,et al.  Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis , 2014, Cell.

[32]  Rajan P Kulkarni,et al.  Classification of large circulating tumor cells isolated with ultra-high throughput microfluidic Vortex technology , 2016, Oncotarget.

[33]  Andrew J Armstrong,et al.  Angiogenesis , Metastasis , and the Cellular Microenvironment Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers , 2011 .

[34]  Tanja Fehm,et al.  Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients , 2009, Breast Cancer Research.

[35]  S. Kurtz,et al.  Quantitative High-Resolution Genomic Analysis of Single Cancer Cells , 2011, PloS one.

[36]  Amy E Herr,et al.  Microfluidic Western blotting , 2012, Proceedings of the National Academy of Sciences.

[37]  Razelle Kurzrock,et al.  PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  E. O’Shea,et al.  Global analysis of protein expression in yeast , 2003, Nature.

[39]  Zhiqiang Liu,et al.  Western Blot: Technique, Theory and Trouble Shooting , 2014, North American journal of medical sciences.

[40]  Liang Cao,et al.  Circulating tumor cells: advances in isolation and analysis, and challenges for clinical applications. , 2014, Pharmacology & therapeutics.

[41]  Geoffrey L. Francis,et al.  Albumin and mammalian cell culture: implications for biotechnology applications , 2010, Cytotechnology.

[42]  John W M Martens,et al.  mRNA and microRNA Expression Profiles in Circulating Tumor Cells and Primary Tumors of Metastatic Breast Cancer Patients , 2011, Clinical Cancer Research.

[43]  S. Jeffrey,et al.  Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow , 2014, BMC Cancer.

[44]  R. Matkowski,et al.  Circulating Tumor , 2014 .

[45]  P. Steeg.  Tumor metastasis: mechanistic insights and clinical challenges , 2006, Nature Medicine.

[46]  Udo Greiser,et al.  Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. , 2003, Cancer research.

[47]  I. Shaifali,et al.  Antibiotic Susceptibility Patterns of Urinary Pathogens in Female Outpatients , 2012, North American journal of medical sciences.

[48]  Siyang Zheng,et al.  Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. , 2007, Journal of chromatography. A.

[49]  J. Bono,et al.  Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents , 2015, British Journal of Cancer.

[50]  Tanja Fehm,et al.  Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients , 2014, Journal of the National Cancer Institute.

[51]  Sean C. Bendall,et al.  A deep profiler's guide to cytometry. , 2012, Trends in immunology.

[52]  Sridhar Ramaswamy,et al.  Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility , 2014, Science.

[53]  L. Frati,et al.  Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  C. Alix-Panabières.  EPISPOT assay: detection of viable DTCs/CTCs in solid tumor patients. , 2012, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[55]  D. Carrasco,et al.  Multiplex Flow Cytometry Barcoding and Antibody Arrays Identify Surface Antigen Profiles of Primary and Metastatic Colon Cancer Cell Lines , 2013, PloS one.

[56]  O. Owoyomi,et al.  Interactions Between Sodium Dodecylsulphate and Triton X-100: Molecular Properties and Kinetics Investigations , 2005 .

[57]  Amy E Herr,et al.  Single cell–resolution western blotting , 2016, Nature Protocols.

[58]  B. Giepmans,et al.  EpCAM: structure and function in health and disease. , 2013, Biochimica et biophysica acta.

[59]  J. Kendall,et al.  Rapid Phenotypic and Genomic Change in Response to Therapeutic Pressure in Prostate Cancer Inferred by High Content Analysis of Single Circulating Tumor Cells , 2014, PloS one.

[60]  K. Pantel,et al.  Heterogeneity of Estrogen Receptor Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients , 2013, PloS one.

[61]  G. Doyle,et al.  Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer , 2009, Journal of oncology.

[62]  Mian Yang,et al.  Toward Analysis of Proteins in Single Cells: A Quantitative Approach Employing Isobaric Tags with MALDI Mass Spectrometry Realized with a Microfluidic Platform. , 2016, Analytical chemistry.

[63]  Amy E. Herr,et al.  Single-cell western blotting , 2014, Nature Methods.

[64]  Mark P Molloy,et al.  Overcoming technical variation and biological variation in quantitative proteomics , 2003, Proteomics.

[65]  Mark M Davis,et al.  Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device , 2009, Proceedings of the National Academy of Sciences.

[66]  Aviv Regev,et al.  Whole exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer , 2014, Nature Biotechnology.

[67]  J. Baselga.  Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. , 2011, The oncologist.

[68]  G. Fleuren,et al.  Epidermal Growth Factor-Like Repeats Mediate Lateral and Reciprocal Interactions of Ep-CAM Molecules in Homophilic Adhesions , 2001, Molecular and Cellular Biology.

[69]  G. Krasnov,et al.  Deregulation of glycolysis in cancer: glyceraldehyde-3-phosphate dehydrogenase as a therapeutic target , 2013, Expert opinion on therapeutic targets.